aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
AsclepiX Therapeutics, founded in Baltimore, United States, is dedicated to transforming the treatment of retinal diseases and cancer. The company's core mission is to design, develop, and deliver novel peptide-based therapies that inhibit key disease pathways. By leveraging pioneering computational biology methods, AsclepiX aims to empower patients and their families globally with groundbreaking treatments that offer improved quality of life.
Notable affiliated individuals include leading experts in the fields of ophthalmology and oncology. The company has attracted significant investment from prominent venture capital firms, underscoring its potential impact. Key achievements include the rapid clinical development of their peptide drug candidates, which have shown promise in preclinical studies. AsclepiX Therapeutics is poised to make a substantial impact on the healthcare industry by offering innovative solutions for challenging diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Peptide Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was AsclepiX Therapeutics founded?
AsclepiX Therapeutics was founded in 2011.
Where is AsclepiX Therapeutics’s headquarters located?
AsclepiX Therapeutics’s headquarters is located in Baltimore, MD, US.
When was AsclepiX Therapeutics’s last funding round?
AsclepiX Therapeutics’s most recent funding round was for $10M (USD) in July 2023.
How many employees does AsclepiX Therapeutics have?
AsclepiX Therapeutics has 16 employees as of Feb 5, 2024.
How much has AsclepiX Therapeutics raised to-date?
As of July 05, 2023, AsclepiX Therapeutics has raised a total of $50M (USD) since Jul 26, 2023.
Add Comparison
Total Raised to Date
$50M
USD
Last Update Jul 26, 2023
Last Deal Details
$10M
USD
Jul 26, 2023
Series A
Total Employees Over Time
16
As of Feb 2024
AsclepiX Therapeutics Address
301 W 29th St
suite 2004
Baltimore,
Maryland
21211
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts